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Several studies have sought to investigate whether changes
in the ability of the immune response to fight malignant
cells could be associated with onset or progression of
cancer, and have linked stress, depression, and lack of
psychosocial support with malignancies.1 Cancer is an
umbrella term that refers to a range of chronic diseases
characterized by uncontrolled growth of cells that invade
tissues and organs and can spread to other parts of
the body. This process has a strong biological basis
and is modulated by psychosocial factors. As do
most psychiatric disorders, cancer has a multifactorial
etiology, including genetic, biological, and environmental
components.
Stress is understood as the experience of a negative
life event or the occurrence of an event that generates
subjective feelings of inadequacy in coping effectiveness.
The brain is the central organ of stress and adaptation.
While acute stress is a normal response associated with
physiological changes necessary to body homeostasis,
chronic stress can be linked to maladaptive brain changes
and a predisposition to development of several diseases.2
A diagnosis of cancer is usually associated with greater
chronic psychological stress than non-neoplastic malig-
nant diseases with similar prognosis.
Psychoendoneuroimmunology studies have demonstrated
the interrelationships between psychological (mental) and
biological (central nervous system, immune, and endo-
crine) processes. This integration assumes that the neuro-
endocrine and immune systems share receptors and
substances with modulating effects on immune events.
In chronic stress, neuroendocrine activation is repre-
sented by stimulation of the sympathetic nervous system
(the main neurotransmitters of which are adrenaline and
noradrenaline) and of the hypothalamic-pituitary-adrenal
axis, with consequent increases in glucocorticoid expression.
This activation, combined with tissue damage resulting
from the malignant neoplasm itself and from interventions
used in cancer treatment (chemotherapy, radiotherapy,
and surgery), is associated with a number of changes
observed in the tumor microenvironment, with conse-
quent stimulation of local inflammatory response.1,3
This increase in local inflammation, represented princi-
pally by elevated production of cytokines such as interleukin
1 (IL-1), IL-6, interferon alpha, and tumor necrosis factor
alpha (TNF-a), will promote a series of cellular and
molecular changes. These events impair regulation of
the immune response, which could enable activation of
oncogenic viruses, alterations in immune cell (including
T-lymphocyte and natural killer cell) response, and
promote tumor cell survival, thus facilitating metastasis
through modulation of angiogenesis, proliferation, inva-
sion, embolization, and colonization of remote sites by
malignant cells. Such effects are modulated by a variety
of neurotransmitter receptors found in leukocytes, stromal
cells, and tumor cells.1
Several studies show that the neurotransmitter serotonin
plays important roles in immune regulation, as a series of
immune system cells express serotonin receptors. It is
therefore expected that pharmacological modulation of
the serotonin system would be associated with immuno-
modulatory effects, which could be related to a change in
progression of inflammation-based diseases such as
cancer. Neutrophil and macrophage chemotaxis, migra-
tion of dendritic cells, antigen presentation with subse-
quent generation of immune memory (innate and acquired
immune response), phagocytosis, opsonization, decreased
TNF-a and IL-12, IL-1, increased IL-6, IL-8, and IL-10,
cellular differentiation (monocytes, macrophages), and
apoptosis are all events that are modulated to some
extent by serotonergic transmission.4
Depressive symptoms are three times more pre-
valent in people with cancer than expected in the general
population, with the highest rates found near the time of
diagnosis. This higher prevalence is due to a number of
predisposing factors, not only demographic and medical,
but also those associated with the underlying disease and
its inflammatory process, which can be associated both
with the pathophysiology of depression and with tumor
growth.5 There is a two-way relationship between stress/
chronic depression and inflammation; stress interferes
with pathophysiological mechanisms associated with
inflammation, while the inflammatory exacerbation site
acts as a stimulus to the central nervous system, pro-
viding feedback and impairing serotonergic and dopami-
nergic transmission.3 These neurotransmitter changes
predispose patients to a depressive state, with a
continuum of symptoms ranging from non-pathological
sadness, through adjustment disorder with predominant
depressive symptoms, to frank depressive disorder.5
Fatigue and energy loss are common symptoms, and
are important components of sickness behavior in these
patients.
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Currently, it is acknowledged that chronic stress and
depression have a negative impact on patients with cancer,
mainly affecting their quality of life and disease progres-
sion. Depression is an independent predictor of worse
prognosis and poor quality of life in these patients; it is
associated with impaired coping with the disease, poorer
treatment adherence, faster progression to advanced
cancer, longer hospital stays, worse depressive symp-
toms during chemotherapy in untreated patients, and
higher mortality, including by suicide.
It is well known that combined pharmacotherapeutic
and psychosocial interventions can alleviate the stress
response, enhance quality of life, and improve prognosis.5
Selective serotonin reuptake inhibitors are drugs of
choice in this patient population, given their potential anti-
inflammatory (microglia), antitumor (apoptosis), and immu-
nomodulatory properties, but the clinical significance of
these immunological and cellular effects is still unclear.6
An individualized and integrated approach that addres-
ses organic and psychosocial dimensions is particularly
important when treating patients with malignancies.5
However, data are still lacking to support more effective
management strategies. Topics for investigation include
drugs with cellular and molecular targets that modulate
inflammation,1 establishing which non-pharmacological
interventions are most effective, and determining the
most opportune time for implementation of such interven-
tions.5 Psycho-oncology is a vast, incipient field for future
research.
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